May 2, 2014
Otsuka Pharmaceutical said on April 30 that Deltyba (delamanid), a proprietary novel treatment for multidrug-resistant tuberculosis (MDR-TB), has won the world’s first regulatory approval in Europe. Deltyba, approved on April 28, has a new mode of action that interferes with...read more